These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1250 related articles for article (PubMed ID: 26051217)

  • 41. Epigenetic reader BRD4 inhibition as a therapeutic strategy to suppress E2F2-cell cycle regulation circuit in liver cancer.
    Hong SH; Eun JW; Choi SK; Shen Q; Choi WS; Han JW; Nam SW; You JS
    Oncotarget; 2016 May; 7(22):32628-40. PubMed ID: 27081696
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Opposing effects of cancer-type-specific SPOP mutants on BET protein degradation and sensitivity to BET inhibitors.
    Janouskova H; El Tekle G; Bellini E; Udeshi ND; Rinaldi A; Ulbricht A; Bernasocchi T; Civenni G; Losa M; Svinkina T; Bielski CM; Kryukov GV; Cascione L; Napoli S; Enchev RI; Mutch DG; Carney ME; Berchuck A; Winterhoff BJN; Broaddus RR; Schraml P; Moch H; Bertoni F; Catapano CV; Peter M; Carr SA; Garraway LA; Wild PJ; Theurillat JP
    Nat Med; 2017 Sep; 23(9):1046-1054. PubMed ID: 28805821
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Synergistic in-vitro effects of combining an antiglycolytic, 3-bromopyruvate, and a bromodomain-4 inhibitor on U937 myeloid leukemia cells.
    Kapp N; Stander XX; Stander BA
    Anticancer Drugs; 2018 Jun; 29(5):429-439. PubMed ID: 29561307
    [TBL] [Abstract][Full Text] [Related]  

  • 44. SPOP-mediated degradation of BRD4 dictates cellular sensitivity to BET inhibitors.
    Dai X; Wang Z; Wei W
    Cell Cycle; 2017; 16(24):2326-2329. PubMed ID: 29108467
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Identification of a selective BRD4 PROTAC with potent antiproliferative effects in AR-positive prostate cancer based on a dual BET/PLK1 inhibitor.
    Hu R; Wang WL; Yang YY; Hu XT; Wang QW; Zuo WQ; Xu Y; Feng Q; Wang NY
    Eur J Med Chem; 2022 Jan; 227():113922. PubMed ID: 34700270
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Bromodomain-Containing Protein 4 (BRD4) Inhibition Sensitizes Palomid 529-Induced Anti-Renal Cell Carcinoma Cell Activity in Vitro and in Vivo.
    Xing ZY; Wang Y; Cheng L; Chen J; He XZ; Xing W
    Cell Physiol Biochem; 2018; 50(2):640-653. PubMed ID: 30308518
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Synthesis and evaluation of novel dual BRD4/HDAC inhibitors.
    Amemiya S; Yamaguchi T; Hashimoto Y; Noguchi-Yachide T
    Bioorg Med Chem; 2017 Jul; 25(14):3677-3684. PubMed ID: 28549889
    [TBL] [Abstract][Full Text] [Related]  

  • 48. A New Quinoline BRD4 Inhibitor Targets a Distinct Latent HIV-1 Reservoir for Reactivation from Other "Shock" Drugs.
    Abner E; Stoszko M; Zeng L; Chen HC; Izquierdo-Bouldstridge A; Konuma T; Zorita E; Fanunza E; Zhang Q; Mahmoudi T; Zhou MM; Filion GJ; Jordan A
    J Virol; 2018 May; 92(10):. PubMed ID: 29343578
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Cellular Resistance Mechanisms to Targeted Protein Degradation Converge Toward Impairment of the Engaged Ubiquitin Transfer Pathway.
    Ottis P; Palladino C; Thienger P; Britschgi A; Heichinger C; Berrera M; Julien-Laferriere A; Roudnicky F; Kam-Thong T; Bischoff JR; Martoglio B; Pettazzoni P
    ACS Chem Biol; 2019 Oct; 14(10):2215-2223. PubMed ID: 31553577
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Disruption of BRD4 at H3K27Ac-enriched enhancer region correlates with decreased c-Myc expression in Merkel cell carcinoma.
    Sengupta D; Kannan A; Kern M; Moreno MA; Vural E; Stack B; Suen JY; Tackett AJ; Gao L
    Epigenetics; 2015; 10(6):460-6. PubMed ID: 25941994
    [TBL] [Abstract][Full Text] [Related]  

  • 51. BET inhibitors induce apoptosis through a MYC independent mechanism and synergise with CDK inhibitors to kill osteosarcoma cells.
    Baker EK; Taylor S; Gupte A; Sharp PP; Walia M; Walsh NC; Zannettino AC; Chalk AM; Burns CJ; Walkley CR
    Sci Rep; 2015 May; 5():10120. PubMed ID: 25944566
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Dual PI3K-BRD4 Inhibitor SF1126 Inhibits Colorectal Cancer Cell Growth in Vitro and in Vivo.
    Qin AC; Li Y; Zhou LN; Xing CG; Lu XS
    Cell Physiol Biochem; 2019; 52(4):758-768. PubMed ID: 30933440
    [TBL] [Abstract][Full Text] [Related]  

  • 53. The bromodomain and extra-terminal inhibitor CPI203 enhances the antiproliferative effects of rapamycin on human neuroendocrine tumors.
    Wong C; Laddha SV; Tang L; Vosburgh E; Levine AJ; Normant E; Sandy P; Harris CR; Chan CS; Xu EY
    Cell Death Dis; 2014 Oct; 5(10):e1450. PubMed ID: 25299775
    [TBL] [Abstract][Full Text] [Related]  

  • 54. EGFR-mediated signaling pathway influences the sensitivity of oral squamous cell carcinoma to JQ1.
    Liu X; Li Q; Huang P; Tong D; Wu H; Zhang F
    J Cell Biochem; 2018 Oct; 119(10):8368-8377. PubMed ID: 30687956
    [TBL] [Abstract][Full Text] [Related]  

  • 55. BET inhibitor OTX015 targets BRD2 and BRD4 and decreases c-MYC in acute leukemia cells.
    Coudé MM; Braun T; Berrou J; Dupont M; Bertrand S; Masse A; Raffoux E; Itzykson R; Delord M; Riveiro ME; Herait P; Baruchel A; Dombret H; Gardin C
    Oncotarget; 2015 Jul; 6(19):17698-712. PubMed ID: 25989842
    [TBL] [Abstract][Full Text] [Related]  

  • 56. The BET bromodomain inhibitor CPI203 improves lenalidomide and dexamethasone activity in
    Díaz T; Rodríguez V; Lozano E; Mena MP; Calderón M; Rosiñol L; Martínez A; Tovar N; Pérez-Galán P; Bladé J; Roué G; de Larrea CF
    Haematologica; 2017 Oct; 102(10):1776-1784. PubMed ID: 28751557
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Different Degradation Mechanisms of Inhibitor of Apoptosis Proteins (IAPs) by the Specific and Nongenetic IAP-Dependent Protein Eraser (SNIPER).
    Ohoka N; Ujikawa O; Shimokawa K; Sameshima T; Shibata N; Hattori T; Nara H; Cho N; Naito M
    Chem Pharm Bull (Tokyo); 2019 Mar; 67(3):203-209. PubMed ID: 30369550
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Design and characterization of bivalent BET inhibitors.
    Tanaka M; Roberts JM; Seo HS; Souza A; Paulk J; Scott TG; DeAngelo SL; Dhe-Paganon S; Bradner JE
    Nat Chem Biol; 2016 Dec; 12(12):1089-1096. PubMed ID: 27775715
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Resistance to everolimus driven by epigenetic regulation of MYC in ER+ breast cancers.
    Bihani T; Ezell SA; Ladd B; Grosskurth SE; Mazzola AM; Pietras M; Reimer C; Zinda M; Fawell S; D'Cruz CM
    Oncotarget; 2015 Feb; 6(4):2407-20. PubMed ID: 25537515
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Selective Small Molecule Induced Degradation of the BET Bromodomain Protein BRD4.
    Zengerle M; Chan KH; Ciulli A
    ACS Chem Biol; 2015 Aug; 10(8):1770-7. PubMed ID: 26035625
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 63.